Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fish oil triglyceride + AquaCelle is a specialized nutraceutical formulation that combines omega-3 fatty acids in their natural triglyceride form with the proprietary AquaCelle self-emulsifying drug delivery system (SEDDS). Developed by Pharmako Biotechnologies, the AquaCelle technology consists of a specific blend of surfactants and lipid components that spontaneously form micelle-like structures upon contact with the aqueous environment of the gastrointestinal tract. This mechanism significantly enhances the bioavailability and absorption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), particularly when consumed without a high-fat meal, which is typically required for optimal absorption of standard fish oils. The formulation is utilized to support cardiovascular health, reduce systemic inflammation, and manage lipid profiles by modulating lipid metabolism and inflammatory signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fish oil triglyceride + AquaCelle.